AbbVie (ABBV): Reiterating Top Pick - Jefferies

November 1, 2016 7:16 AM EDT
Get Alerts ABBV Hot Sheet
Price: $61.15 -0.37%

Rating Summary:
    10 Buy, 12 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade ABBV Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Jefferies analyst, Jeffrey Holford, reiterated his Buy rating on shares of Abbvie (NYSE: ABBV) and highlighted the company as his top pick noting that Humira is differentiated from Enbrel by its breadth and strength of indications, growth profile and formulary positioning.

The analyst remain confident that Humira can achieve double digit growth through 2017/18. He also believes that fears of indication based pricing are overdone given contracting for 2017/18 is largely completed with none evident.

The analyst's model is well above consensus revenue and EPS mid-term. No change to the price target of $90.

For an analyst ratings summary and ratings history on Abbvie click here. For more ratings news on Abbvie click here.

Shares of Abbvie closed at $55.78 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment